Abstract

BackgroundTo evaluate the dosimetric performance of multi-channel vaginal cylinder (MCVC) against interstitial brachytherapy (ISBT) for the treatment of vaginal tumors.MethodsVaginal tumors with extension of > 0.5 cm and ≤ 2 cm from the lateral vaginal wall and/or ≤ 1 cm in height above the vaginal vault were retrospectively selected from a ISBT registry trial database. The selected patients were treated with ISBT and targets included the intermediate (IRCTV) or high-risk (HRCTV) clinical target volumes. For technique comparison, a 35 mm MCVC was registered with the interstitial intra-vaginal cylinder. Bladder and rectum contours were transferred from the ISBT to the MCVC-BT plans. Vaginal mucosa was achieved by 3 mm uniform expansion from cylinder surface. Both the ISBT and MCVC-BT plans were optimized using the Inverse Planning Simulated Annealing optimization algorithm. After normalizing target D90 to 700 cGy, dose to organs at risk were measured and compared between ISBT and MCVC plans.ResultsSix interstitial patient plans met the inclusion criteria for this study. Four patients had vaginal primaries and two recurrent cancers in the vagina. Lower doses to bladder and rectum were seen with ISBT plans. In half of the MCVC plans, the rectal dose met the recommended constraints. For plans in which the rectal constraint was not met, the target volumes were abutting the rectum and had a cranial-caudal length ≥ 5 cm. Dose to vaginal mucosa was lower in ISBT plans directed to the HRCTVs, although no difference was seen in circumferential IRCTVs.ConclusionsOverall, ISBT results in decreased dose to OARs as compared to MCVC. However, MCVC BT results in acceptable doses to OARs with possible improvement in vaginal doses for circumferential targets. Careful consideration to tumor geometry and location may help guide optimal techniques in vaginal tumor brachytherapy.

Highlights

  • To evaluate the dosimetric performance of multi-channel vaginal cylinder (MCVC) against interstitial brachytherapy (ISBT) for the treatment of vaginal tumors

  • The goal of this study is to evaluate the dosimetric performance of MCVC against interstitial BT (ISBT) in patients with vaginal tumors thicker than 5 mm, previously treated with ISBT

  • The High-risk clinical target volumes (HRCTV) was equal to the Intermediate-risk clinical target volume (IRCTV) and only one volume was treated

Read more

Summary

Introduction

To evaluate the dosimetric performance of multi-channel vaginal cylinder (MCVC) against interstitial brachytherapy (ISBT) for the treatment of vaginal tumors. Brachytherapy (BT) plays an important role in the radiation treatment of vaginal tumors. The most common BT forms of treatment for vaginal tumors employ a single-channel vaginal cylinder (SCVC) and the interstitial BT (ISBT) techniques. The American Brachytherapy Society has published guidelines on the treatment of vaginal cancers and suggests that ISBT is the preferred modality for lesions thicker than 5 mm [1]. For these tumors, SCVC brachytherapy treatment results in high doses to the vaginal mucosa and pelvic organs as compared to ISBT. Interstitial brachytherapy treatment may be more invasive, resource intensive and inconvenient, as it usually requires hospital admission, general anesthesia and carries risks for pain and acute complications from the procedure

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call